Comparative studies on the potential use of ¹⁷⁷Lu-based radiopharmaceuticals for the palliative therapy of bone metastases

References

• Abbasi I. 2015. Studies on the labeling of ethylenediaminetetramethylene phosphonic acid, methylene diphosphonate, sodium pyrophosphate and hydroxyapatite with Lutetium-177 for use in nuclear medicine. World J Nucl Med. 14(2):95–100.
   PubMedGoogle Scholar
• Abram SE. 2006. Radiopharmaceutical therapy for palliation of bone pain from osseous metastases. Yearb Anesthesiol Pain Manag. 2006:256–257.
   Google Scholar
• Anderson P, Nuñez R. 2007. Samarium lexidronam (153Sm-EDTMP): skeletal radiation for osteoblastic bone metastases and osteosarcoma. Expert Rev Anticancer Ther. 7(11):1517–1527.
   PubMed Web of Science ®Google Scholar
• Andersson M, Johansson L, Eckerman K, Mattsson S. 2017. IDAC-Dose 2.1, an internal dosimetry program for diagnostic nuclear medicine based on the ICRP adult reference voxel phantoms. EJNMMI Res. 7(1):88.
   PubMedGoogle Scholar
• Bahrami-Samani A, Anvari A, Jalilian AR, Shirvani-Arani S, Yousefnia H, Aghamiri MR, Ghannadi-Maragheh M. 2012. Production, quality control and pharmacokinetic studies of 177Lu-EDTMP for human bone pain palliation therapy trials. Iran J Pharm Res. 11(1):137–144.
   PubMed Web of Science ®Google Scholar
• Bal C, Arora G, Kumar P, Damle N, Das T, Chakraborty S, Banerjee S, Venkatesh M, Zaknun JJ, Pillai MRA. 2016. Pharmacokinetic, dosimetry and toxicity study of 177 Lu-EDTMP in patients: Phase 0/I study. Curr Radiopharm. 9:71–84.
   PubMed Web of Science ®Google Scholar
• Bai HS, Jin HX, Fan HQ, Du J, Wang F, Chen DM, Cheng Z. 1998. Study on analysis of 153 Sm-EDTMP stability in vitro and vivo by HPLC. J Radioanal Nucl Chem. 236(1–2):87–95.
   Web of Science ®Google Scholar
• Bolch WE, Eckerman KF, Sgouros G, Thomas SR. 2009. MIRD pamphlet no. 21: a generalized schema for radiopharmaceutical dosimetry–standardization of nomenclature. J Nucl Med. 50(3):477–484.
   PubMed Web of Science ®Google Scholar
• Chakraborty S, Das T, Banerjee S, Balogh L, Chaudhari PR, Sarma HD, Polyák A, Máthé D, Venkatesh M, Janoki G, et al. 2008. 177 Lu-EDTMP: a viable bone pain palliative in skeletal metastasis. Cancer Biother Radiopharm. 23(2):202–213.
   PubMed Web of Science ®Google Scholar
• Chakraborty S, Das T, Sarma HD, Venkatesh M, Banerjee S. 2008. Comparative studies of 177Lu-EDTMP and 177Lu-DOTMP as potential agents for palliative radiotherapy of bone metastasis. Appl Radiat Isot. 66(9):1196–1205.
   PubMed Web of Science ®Google Scholar
• Daha FJ, Shafiei M, Sheibani S, Tavakoli YH, Mazidi M, Mirfalah MH, Babaei MH. 2010. Production of 177Lu and formulation of Ethylene diamine tetramethylene phosphonate (EDTMP) kits as a bone-seeking radiopharmaceutical. Iran J Radiat Res. 7:229–234.
   Google Scholar
• Das T, Chakraborty S, Sarma HD, Tandon P, Banerjee S, Venkatesh M, Pillai M. 2009. 170Tm-EDTMP: a potential cost-effective alternative to 89SrCl2 for bone pain palliation. Nucl Med Biol [Internet]. 36(5):561–568.
   PubMed Web of Science ®Google Scholar
• Das T, Sarma HD, Shinto A, Kamaleshwaran KK, Banerjee S. 2014. Formulation, preclinical evaluation, and preliminary clinical investigation of an in-house freeze-dried EDTMP kit suitable for the preparation of 177 Lu-EDTMP. Cancer Biother Radiopharm. 29(10):412–421.
   PubMed Web of Science ®Google Scholar
• De Ligny CL, Gelsema WJ, Tji TG, Huigen YM, Vink HA. 1990. Bone seeking radiopharmaceuticals. Int J Radiat Appl Instrumentation. 17(2):161–179.
   PubMedGoogle Scholar
• Eckerman KF, Sjoreen AL. 2003. Radiological toolbox user’s manual. [Oak Ridge laboratory, USA].
   Google Scholar
• Finlay IG, Mason MD, Shelley M. 2005. Radioisotopes for the palliation of metastatic bone cancer: a systematic review. Lancet Oncol. 6(6):392–400.
   PubMed Web of Science ®Google Scholar
• Goyal J, Antonarakis ES. 2012. Bone-targeting radiopharmaceuticals for the treatment of prostate cancer with bone metastases. Cancer Lett. 323(2):135–146.
   PubMed Web of Science ®Google Scholar
• Guerra Liberal FDC, Tavares AAS, Tavares J. 2014. Comparative analysis of 11 different radioisotopes for palliative treatment of bone metastases by computational methods. Med Phys. 41:114101.
   PubMed Web of Science ®Google Scholar
• Guerra Liberal FDC, Tavares AAS, Tavares J. 2016. Palliative treatment of metastatic bone pain with radiopharmaceuticals: a perspective beyond Strontium-89 and Samarium-153. Appl Radiat Isot. 110:87–99.
   PubMed Web of Science ®Google Scholar
• Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Ping Thang S, Akhurst T, Iravani A, Kong G, Ravi Kumar A, Murphy DG, et al. 2018. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 19(6):825–833.
   PubMed Web of Science ®Google Scholar
• ICRP 137. 2017. Occupational intakes of radionuclides: part 3. Ann ICRP. 46:7–486.
   Google Scholar
• ICRP. 2016. Occupational intakes of radionuclides: part 4. Ann ICRP. 36:1–337.
   Google Scholar
• ICRP. 2019. Occupational intakes of radionuclides: part 4 ICRP Publication 141. Ann ICRP. 48.
   Google Scholar
• Kálmán FK, Király R, Brücher E. 2008. Stability constants and dissociation rates of the EDTMP complexes of Samarium(III) and Yttrium(III). Eur J Inorg Chem. 2008(30):4719–4727.
   Google Scholar
• Kam BLR, Teunissen JJM, Krenning EP, De Herder WW, Khan S, Van Vliet EI, Kwekkeboom DJ. 2012. Lutetium-labelled peptides for therapy of neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 39(S1):103–112.
   Google Scholar
• Lam M. 2009. Improving radionuclide therapy in prostate cancer patients with metastatic bone pain [PhD thesis]. The Netherlands: Utrecht University.
   Google Scholar
• Leggett RW, Eckerman KF. 2001. A systemic biokinetic model for polonium. Sci Total Environ. 275(1–3):109–125.
   PubMed Web of Science ®Google Scholar
• Liberal F, Tavares AAS, Tavares J. 2017. Computational modeling of radiobiological effects in bone metastases for different radionuclides. Int J Radiat Biol. 93(6):627–636.
   PubMed Web of Science ®Google Scholar
• Mattsson S, Johansson L, Leide Svegborn S, Liniecki J, Noßke D, Riklund K.Å, Stabin M, Taylor D, Bolch W, Carlsson S, et al. 2015. ICRP publication 128: radiation dose to patients from radiopharmaceuticals: a compendium of current information related to frequently used substances. Ann ICRP. 44(2_suppl):7–321.
   PubMedGoogle Scholar
• Mostafa MYA, Zakaly HMH, Zhukovsky M. 2019. Assessment of exposure after injection of 99mTc-labeled intact monoclonal antibodies and their fragments into humans. Radiol Phys Technol. 12(1):96–104.
   PubMed Web of Science ®Google Scholar
• Paquet F, Bailey MR, Leggett RW, Lipsztein J, Fell TP, Smith T, Nosske D, Eckerman KF, Berkovski V, Ansoborlo E, et al. 2016. ICRP publication 134: occupational intakes of radionuclides: part 2. Ann ICRP. 45(3–4):7–349.
   PubMedGoogle Scholar
• Insel PM, Turner RD. 2007. Nutrition [Internet]. Third Edit. [place unknown]: Jones & Bartlett Publishers. Available from: https://www.amazon.com/Nutrition-Paul-Insel/dp/076374252X
   Google Scholar
• Sharma S, Singh B, Koul A, Mittal BR. 2017. Comparative therapeutic efficacy of 153Sm-EDTMP and 177Lu-EDTMP for bone pain palliation in patients with skeletal metastases: patients' pain score analysis and personalized dosimetry. Front Med. 4. DOI: 10.3389/fmed.2017.00046
   Web of Science ®Google Scholar
• Tavares AAS, Tavares J. 2010a. 99m Tc Auger electrons for targeted tumour therapy: a review. Int J Radiat Biol. 86(4):261–270.
   PubMed Web of Science ®Google Scholar
• Tavares AAS, Tavares J. 2010b. Evaluating 99m Tc Auger electrons for targeted tumor radiotherapy by computational methods. Med Phys. 37(7Part1):3551–3559.
   PubMedGoogle Scholar
• Tavares AAS, Tavares J. 2011. 99m Tc Auger electrons – analysis on the effects of low absorbed doses by computational methods. Appl Radiat Isot. 69(3):607–608.
   PubMed Web of Science ®Google Scholar
• Taylor DM, Leggett RW. 2003. A generic biokinetic model for predicting the behaviour of the lanthanide elements in the human body. Radiat Prot Dosimetry. 105(1–4):193–198.
   PubMed Web of Science ®Google Scholar
• Vigna L, Matheoud R, Ridone S, Arginelli D, Della Monica P, Rudoni M, Inglese E, Brambilla M. 2011. Characterization of the [153Sm]Sm-EDTMP pharmacokinetics and estimation of radiation absorbed dose on an individual Basis. Phys Med. 27(3):144–152.
   PubMed Web of Science ®Google Scholar
• Wilky BA. 2013. Beyond palliation: therapeutic applications of 153Samarium-EDTMP. Clin Exp Pharmacol. 03(03):1000131.
   Google Scholar
• Yousefnia H, Zolghadri S, Sadeghi HR, Naderi M, Jalilian AR, Shanehsazzadeh S. 2016. Preparation and biological assessment of 177 Lu-BPAMD as a high potential agent for bone pain palliation therapy: comparison with 177 Lu-EDTMP. J Radioanal Nucl Chem. 307(2):1243–1251.
   Web of Science ®Google Scholar
• Zakaly HMH, Mostafa MYA, Zhukovsky M. 2019. Dosimetry assessment of injected 89Zr-labeled monoclonal antibodies in humans. Radiat Res. 191:466–474.
   PubMed Web of Science ®Google Scholar